{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:18:11Z","timestamp":1788923891330,"version":"build-2803163510"},"reference-count":149,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund","award":["TKP2021-EGA-10"],"award-info":[{"award-number":["TKP2021-EGA-10"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a chronic autoimmune disease that leads to the destruction of peripheral joint cartilage and bone tissue. Despite the advent of biological therapies in the past decades, the complete remission of RA patients is still out of reach. Therefore, the search for novel therapeutic approaches is still open in the field of RA. Proteasome inhibitors (PIs) were originally designed to be used in hematological malignancies like multiple myeloma. However, evidence has shown that they are potent inhibitors of the NF-\u03baB pathway, which plays a pivotal role in inflammatory processes and RA. Furthermore, inhibition of cell activation and induction of apoptosis was also reported about PIs. In the present review, we summarize the current knowledge about the potential effects of PIs in RA based on reports from animal and human studies. We believe that there is substantial potential in the use of PIs in RA therapy either alone or in combination with the medications already used.<\/jats:p>","DOI":"10.3390\/ijms26072943","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T12:01:50Z","timestamp":1742817710000},"page":"2943","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Proteasome Inhibitors: Potential in Rheumatoid Arthritis Therapy?"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4702-4096","authenticated-orcid":false,"given":"Okt\u00e1via","family":"Tarj\u00e1nyi","sequence":"first","affiliation":[{"name":"Department of Medical Biology, Medical School, University of Pecs, H-7624 Pecs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Olasz","sequence":"additional","affiliation":[{"name":"Department of Immunology and Biotechnology, Medical School, University of Pecs, H-7624 Pecs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanni","family":"R\u00e1tky","sequence":"additional","affiliation":[{"name":"Department of Medical Biology, Medical School, University of Pecs, H-7624 Pecs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-8541","authenticated-orcid":false,"given":"Gy\u00f6rgy","family":"S\u00e9t\u00e1l\u00f3","sequence":"additional","affiliation":[{"name":"Department of Medical Biology, Medical School, University of Pecs, H-7624 Pecs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7831-1018","authenticated-orcid":false,"given":"Ferenc","family":"Boldizs\u00e1r","sequence":"additional","affiliation":[{"name":"Department of Immunology and Biotechnology, Medical School, University of Pecs, H-7624 Pecs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid Arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid Arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/ar2370","article-title":"Recent Developments in the Immunobiology of Rheumatoid Arthritis","volume":"10","author":"Andersson","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.7326\/0003-4819-117-10-801","article-title":"The Influence of HLA-DRB1 Genes on Disease Severity in Rheumatoid Arthritis","volume":"117","author":"Weyand","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/ng.1076","article-title":"Five Amino Acids in Three HLA Proteins Explain Most of the Association between MHC and Seropositive Rheumatoid Arthritis","volume":"44","author":"Raychaudhuri","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12016-009-8166-6","article-title":"Epigenetics in Rheumatoid Arthritis","volume":"39","author":"Trenkmann","year":"2010","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/art.21575","article-title":"A New Model for an Etiology of Rheumatoid Arthritis: Smoking May Trigger HLA-DR (Shared Epitope)-Restricted Immune Reactions to Autoantigens Modified by Citrullination","volume":"54","author":"Klareskog","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/art.41948","article-title":"Association of Sputum Neutrophil Extracellular Trap Subsets with IgA Anti\u2013Citrullinated Protein Antibodies in Subjects at Risk for Rheumatoid Arthritis","volume":"74","author":"Okamoto","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/annrheumdis-2020-216972","article-title":"Dysbiosis in the Oral Microbiomes of Anti-CCP Positive Individuals at Risk of Developing Rheumatoid Arthritis","volume":"80","author":"Cheng","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/art.40490","article-title":"Modulation of Inflammatory Arthritis in Mice by Gut Microbiota Through Mucosal Inflammation and Autoantibody Generation","volume":"70","author":"Jubair","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/annrheumdis-2016-209206","article-title":"Differential Impact of Obesity on the Pathogenesis of RA or Preclinical Models Is Contingent on the Disease Status","volume":"76","author":"Kim","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/art.23148","article-title":"Differences in Synovial Tissue Infiltrates between Anti-Cyclic Citrullinated Peptide-Positive Rheumatoid Arthritis and Anti-Cyclic Citrullinated Peptide-Negative Rheumatoid Arthritis","volume":"58","author":"Bajema","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF02904814","article-title":"Aggrecan: A Target Molecule of Autoimmune Reactions","volume":"2","author":"Mikecz","year":"1996","journal-title":"Pathol. Oncol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/sj.cr.7290034","article-title":"Isolation and Characteristics of Autoreactive T Cells Specific to Aggrecan G1 Domain from Rheumatoid Arthritis Patients","volume":"10","author":"Li","year":"2000","journal-title":"Cell Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/rheumatology\/keg230","article-title":"Predominant Cellular Immune Response to the Cartilage Autoantigenic G1 Aggrecan in Ankylosing Spondylitis and Rheumatoid Arthritis","volume":"42","author":"Zou","year":"2003","journal-title":"Rheumatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0024-3205(97)00480-3","article-title":"Minireview: Collagen-Induced Arthritis, an Animal Model of Autoimmunity","volume":"61","author":"Myers","year":"1997","journal-title":"Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/art.1780300211","article-title":"Proteoglycan-Induced Arthritis in BALB\/c Mice. Clinical Features and Histopathology","volume":"30","author":"Glant","year":"1987","journal-title":"Arthritis Rheum."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Jang, S., Kwon, E.J., and Lee, J.J. (2022). Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020905"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","article-title":"Fibroblast-like Synoviocytes: Key Effector Cells in Rheumatoid Arthritis","volume":"233","author":"Bartok","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Yoshitomi, H. (2019). Regulation of Immune Responses and Chronic Inflammation by Fibroblast-like Synoviocytes. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01395"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mellado, M., Mart\u00ednez-Mu\u00f1oz, L., Cascio, G., Lucas, P., Pablos, J.L., and Rodr\u00edguez-Frade, J.M. (2015). T Cell Migration in Rheumatoid Arthritis. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00384"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.smim.2013.10.009","article-title":"The Plasticity of Human Treg and Th17 Cells and Its Role in Autoimmunity","volume":"25","author":"Kleinewietfeld","year":"2013","journal-title":"Semin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.18.1.621","article-title":"Phosphorylation Meets Ubiquitination: The Control of NF-\u03baB Activity","volume":"18","author":"Karin","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1038\/sj.onc.1203239","article-title":"Activators and Target Genes of Rel\/NF-\u03baB Transcription Factors","volume":"18","author":"Pahl","year":"1999","journal-title":"Oncogene"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/1529-0131(199811)41:11<1987::AID-ART14>3.0.CO;2-8","article-title":"Nuclear Factor \u03baB\/P50 Activates an Element in the Distal Matrix Metalloproteinase 1 Promoter in Interleukin-1\u03b2-Stimulated Synovial Fibroblasts","volume":"41","author":"Vincenti","year":"1998","journal-title":"Arthritis Rheum."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1006\/bbrc.1999.1551","article-title":"Nuclear Factor \u03baB Activity Is Essential for Matrix Metalloproteinase-1 and -3 Upregulation in Rabbit Dermal Fibroblasts","volume":"264","author":"Bond","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nm1054","article-title":"Selective Inhibition of NF-\u03baB Blocks Osteoclastogenesis and Prevents Inflammatory Bone Destruction in Vivo","volume":"10","author":"Jimi","year":"2004","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.gt.3300461","article-title":"NF-\u03baB as a Target for Anti-Inflammatory Gene Therapy: Suppression of Inflammatory Responses in Monocytic and Stromal Cells by Stable Gene Transfer of I\u03baB\u03b1 CDNA","volume":"4","author":"Makarov","year":"1997","journal-title":"Gene Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1073\/pnas.96.10.5668","article-title":"Defining Therapeutic Targets by Using Adenovirus: Blocking NF-\u03baB Inhibits Both Inflammatory and Destructive Mechanisms in Rheumatoid Synovium but Spares Anti-Inflammatory Mediators","volume":"96","author":"Bondeson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/ni842","article-title":"BAFF-Induced NEMO-Independent Processing of NF-\u03baB2 in Maturing B Cells","volume":"3","author":"Claudio","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nri1838","article-title":"B-Cell Targeting in Rheumatoid Arthritis and Other Autoimmune Diseases","volume":"6","author":"Edwards","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3899\/jrheum.150245","article-title":"Nuclear Factor-\u03baB-Inducing Kinase Is Expressed in Synovial Endothelial Cells in Patients with Early Arthritis and Correlates with Markers of Inflammation: A Prospective Cohort Study","volume":"42","author":"Maijer","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1172\/JCI23763","article-title":"NF-\u03baB-Inducing Kinase Controls Lymphocyte and Osteoclast Activities in Inflammatory Arthritis","volume":"115","author":"Aya","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00002281-200005000-00006","article-title":"Pathogenesis of Bone Erosions in Rheumatoid Arthritis","volume":"12","author":"Goldring","year":"2000","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/jlb.65.6.715","article-title":"TRANCE Is a TNF Family Member That Regulates Dendritic Cell and Osteoclast Function","volume":"65","author":"Wong","year":"1999","journal-title":"J. Leukoc. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/rheumatology\/kem298","article-title":"Signalling, Inflammation and Arthritis: NF-\u03baB and Its Relevance to Arthritis and Inflammation","volume":"47","author":"Simmonds","year":"2008","journal-title":"Rheumatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1038\/sj.onc.1203218","article-title":"Diverse Agents Act at Multiple Levels to Inhibit the Rel\/NF-\u03baB Signal Transduction Pathway","volume":"18","author":"Epinat","year":"1999","journal-title":"Oncogene"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/sj.cdd.4401870","article-title":"Dissection of the NF-\u03baB Signalling Cascade in Transgenic and Knockout Mice","volume":"13","author":"Pasparakis","year":"2006","journal-title":"Cell Death Differ."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6781","DOI":"10.1038\/sj.onc.1209944","article-title":"Unravelling the Complexities of the NF-\u03baB Signalling Pathway Using Mouse Knockout and Transgenic Models","volume":"25","author":"Gerondakis","year":"2006","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1002\/1529-0131(199912)42:12<2532::AID-ANR5>3.0.CO;2-2","article-title":"Suppressed Severity of Collagen-Induced Arthritis by in Vivo Transfection of Nuclear Factor \u03baB Decoy Oligodeoxynucleotides as a Gene Therapy","volume":"42","author":"Tomita","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1084\/jem.20042081","article-title":"I\u03baB Kinase (IKK)\u03b2, but Not IKK\u03b1, Is a Critical Mediator of Osteoclast Survival and Is Required for Inflammation-Induced Bone Loss","volume":"201","author":"Ruocco","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3390\/cells9071627","article-title":"Cell-Type Targeted Nf-Kappab Inhibition for the Treatment of Inflammatory Diseases","volume":"9","author":"Sehnert","year":"2020","journal-title":"Cells"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e024523","DOI":"10.1136\/bmjopen-2018-024523","article-title":"Bortezomib in Antibody-Mediated Autoimmune Diseases (TAVAB): Study Protocol for a Unicentric, Non-Randomised, Non-Placebo Controlled Trial","volume":"9","author":"Kohler","year":"2019","journal-title":"BMJ Open"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The Proteasome Inhibitior Bortezomib Depletes Plasma Cells and Ameliorates Clinical Manifestations of Refractory Systemic Lupus Erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(02)01828-9","article-title":"Anti-Inflammatory Effects of Aspirin and Sodium Salicylate","volume":"447","author":"Amann","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.4049\/jimmunol.156.10.3961","article-title":"Salicylates Inhibit I Kappa B-Alpha Phosphorylation, Endothelial-Leukocyte Adhesion Molecule Expression, and Neutrophil Transmigration","volume":"156","author":"Pierce","year":"1996","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/rheumatology\/keu135","article-title":"Benefits and Risks of Low-Dose Glucocorticoid Treatment in the Patient with Rheumatoid Arthritis","volume":"53","author":"Kavanaugh","year":"2014","journal-title":"Rheumatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/rheumatology\/kew344","article-title":"Adverse Events of Glucocorticoids during Treatment of Rheumatoid Arthritis: Lessons from Cohort and Registry Studies","volume":"55","author":"Bijlsma","year":"2016","journal-title":"Rheumatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.autrev.2008.07.029","article-title":"Predictivity and Sensitivity of Animal Models of Arthritis","volume":"8","author":"Cuzzocrea","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nature02119","article-title":"Altered Thymic T-Cell Selection Due to a Mutation of the ZAP-70 Gene Causes Autoimmune Arthritis in Mice","volume":"426","author":"Sakaguchi","year":"2003","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic Mice Expressing Human Tumour Necrosis Factor: A Predictive Genetic Model of Arthritis","volume":"10","author":"Keffer","year":"1991","journal-title":"EMBO J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1002\/art.27614","article-title":"Impaired Activation-Induced Cell Death Promotes Spontaneous Arthritis in Antigen (Cartilage Proteoglycan)-Specific T Cell Receptor-Transgenic Mice","volume":"62","author":"Boldizsar","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1002\/art.10637","article-title":"Mice Lacking Endogenous Major Histocompatibility Complex Class II Develop Arthritis Resembling Psoriatic Arthritis at an Advanced Age","volume":"46","author":"Zhang","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1084\/jem.146.3.857","article-title":"Autoimmunity to type II collagen: An experimental model of arthritis","volume":"146","author":"Trentham","year":"1977","journal-title":"J. Exp. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/art.30261","article-title":"Proteoglycan-Induced Arthritis and Recombinant Human Proteoglycan Aggrecan G1 Domain-Induced Arthritis in BALB\/c Mice Resembling Two Subtypes of Rheumatoid Arthritis","volume":"63","author":"Glant","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6145810","DOI":"10.1155\/2016\/6145810","article-title":"Enigma of IL-17 and Th17 Cells in Rheumatoid Arthritis and in Autoimmune Animal Models of Arthritis","volume":"2016","author":"Kugyelka","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.4049\/jimmunol.148.7.2103","article-title":"Induction of Arthritis with Monoclonal Antibodies to Collagen","volume":"148","author":"Terato","year":"1992","journal-title":"J. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3181\/00379727-91-22179","article-title":"Development of Arthritis, Periarthritis and Periostitis in Rats given Adjuvants","volume":"91","author":"Pearson","year":"1956","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/art.1780200714","article-title":"Zymosan\u2014Induced Arthritis","volume":"20","author":"Keystone","year":"1977","journal-title":"Arthritis Rheum."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1084\/jem.146.6.1585","article-title":"Arthritis in Rats after Systemic Injection of Streptococcal Cells or Cell Walls","volume":"146","author":"Cromartie","year":"1977","journal-title":"J. Exp. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2022 Update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/ar300","article-title":"NF-\u03baB in Rheumatoid Arthritis: A Pivotal Regulator of Inflammation, Hyperplasia, and Tissue Destruction","volume":"3","author":"Makarov","year":"2001","journal-title":"Arthritis Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3892\/br.2012.42","article-title":"TNF Inhibitor Therapy for Rheumatoid Arthritis","volume":"1","author":"Ma","year":"2013","journal-title":"Biomed. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/DDDT.S41645","article-title":"Rituximab for the Treatment of Rheumatoid Arthritis: An Update","volume":"8","author":"Mok","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7","volume":"174","author":"Linsley","year":"1991","journal-title":"J. Exp. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting Interleukin-6 in Inflammatory Autoimmune Diseases and Cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2147\/DDDT.S100302","article-title":"Profile of Sarilumab and Its Potential in the Treatment of Rheumatoid Arthritis","volume":"11","author":"Raimondo","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/rheumatology\/key361","article-title":"Safety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients with Rheumatoid Arthritis","volume":"58","author":"Emery","year":"2019","journal-title":"Rheumatology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"Jak Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data","volume":"13","author":"Harrington","year":"2020","journal-title":"J. Inflamm. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR Definition of Difficult-To-Treat Rheumatoid Arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/rheumatology\/keae544","article-title":"Difficult-to-Treat Rheumatoid Arthritis: What Have We Learned and What Do We Still Need to Learn?","volume":"64","author":"Hofman","year":"2025","journal-title":"Rheumatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1093\/emboj\/17.24.7151","article-title":"The Ubiquitin-Proteasome Pathway: On Protein Death and Cell Life","volume":"17","author":"Ciechanover","year":"1998","journal-title":"EMBO J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"29641","DOI":"10.1074\/jbc.274.42.29641","article-title":"Molecular Dissection of the Interactions among I\u03baB\u03b1, FWD1, and Skp1 Required for Ubiquitin-Mediated Proteolysis of I\u03baB\u03b1","volume":"274","author":"Hattori","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome Inhibitors\u2014Molecular Basis and Current Perspectives in Multiple Myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/j.1460-2075.1992.tb05379.x","article-title":"In Vivo Function of the Proteasome in the Ubiquitin Pathway","volume":"11","author":"Seufert","year":"1992","journal-title":"EMBO J."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Opresko, L.K., Gephart, J.M., and Mann, M.B. (2004). Ubiquitin-Mediated Proteolysis: An Ideal Pathway for Systems Biology Analysis. Advances in Systems Biology; Advances in Experimental Medicine and Biology, Springer.","DOI":"10.1007\/978-1-4419-8861-4"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1146\/annurev.bi.61.070192.003553","article-title":"The Ubiquitin System for Protein Degradation","volume":"61","author":"Hershko","year":"1992","journal-title":"Annu. Rev. Biochem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The Ubiquitin System","volume":"67","author":"Hershko","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1152\/physrev.00027.2001","article-title":"The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction","volume":"82","author":"Glickman","year":"2002","journal-title":"Physiol. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1016\/S0021-9258(18)34958-5","article-title":"Ubiquitin-Activating Enzyme. Mechanism and Role in Protein-Ubiquitin Conjugation","volume":"257","author":"Haas","year":"1982","journal-title":"J. Biol. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Liu, W., Tang, X., Qi, X., Fu, X., Ghimire, S., Ma, R., Li, S., Zhang, N., and Si, H. (2020). The Ubiquitin Conjugating Enzyme: An Important Ubiquitin Transfer Platform in Ubiquitin-Proteasome System. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082894"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrm.2016.91","article-title":"Structural Insights into the Catalysis and Regulation of E3 Ubiquitin Ligases","volume":"17","author":"Buetow","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Toma-Fukai, S., and Shimizu, T. (2021). Structural Diversity of Ubiquitin E3 Ligase. Molecules, 26.","DOI":"10.3390\/molecules26216682"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1096\/fj.02-0654rev","article-title":"Regulation of Apoptosis: The Ubiquitous Way","volume":"17","author":"Yang","year":"2003","journal-title":"FASEB J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and P53 in Oncogenesis and Cancer Therapy","volume":"13","author":"Wade","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_86","first-page":"173","article-title":"Nutlin-3, A P53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment","volume":"18","year":"2018","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1042\/BST20220352","article-title":"Small Molecule and Peptide Inhibitors of \u0392TrCP and the \u0392TrCP\u2013NRF2 Protein\u2013Protein Interaction","volume":"51","author":"Jaffry","year":"2023","journal-title":"Biochem. Soc. Trans."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"15671","DOI":"10.1073\/pnas.95.26.15671","article-title":"Role of the Proteasome and NF-\u03baB in Streptococcal Cell Wall-Induced Polyarthritis","volume":"95","author":"Palombella","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1042\/BST0350012","article-title":"Functions of the Proteasome: From Protein Degradation and Immune Surveillance to Cancer Therapy","volume":"35","author":"Goldberg","year":"2007","journal-title":"Biochem. Soc. Trans."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1146\/annurev.biochem.78.082307.091526","article-title":"Regulation and Cellular Roles of Ubiquitin-Specific Deubiquitinating Enzymes","volume":"78","author":"Ventii","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Schmidt, C., Berger, T., Groettrup, M., and Basler, M. (2018). Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02386"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.4049\/jimmunol.1900182","article-title":"Immunoproteasome Inhibition Selectively Kills Human CD14+ Monocytes and as a Result Dampens IL-23 Secretion","volume":"203","author":"Basler","year":"2019","journal-title":"J. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bbamcr.2004.10.004","article-title":"The Proteasome and MHC Class I Antigen Processing","volume":"1695","author":"Kloetzel","year":"2004","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1084\/jem.187.1.97","article-title":"Immunoproteasome Assembly: Cooperative Incorporation of Interferon \u03b3 (IFN-\u03b3)-Inducible Subunits","volume":"187","author":"Griffin","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/jpet.111.187542","article-title":"Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein\/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with","volume":"341","author":"Verbrugge","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.molimm.2012.02.047","article-title":"Constitutive and Immunoproteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity","volume":"51","author":"Huber","year":"2012","journal-title":"Mol. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"119.4","DOI":"10.4049\/jimmunol.188.Supp.119.4","article-title":"Targeting the Immunoproteasome with the Second Generation Proteasome Inhibitor ONX 0914: Effects on IFN-Alpha-Induced Monocyte-Derived Dendritic Cells (119.4)","volume":"188","author":"Verbrugge","year":"2012","journal-title":"J. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/rheumatology\/ken042","article-title":"Autoimmune Reactivity against the 20S-Proteasome Includes Immunosubunits LMP2 (\u03921i), MECL1 (\u03922i) and LMP7 (\u03925i)","volume":"47","author":"Scheffler","year":"2008","journal-title":"Rheumatology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/art.21782","article-title":"Tissue-Specific up-Regulation of the Proteasome Subunit \u03925i (LMP7) in Sj\u00f6gren\u2019s Syndrome","volume":"54","author":"Egerer","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"21170","DOI":"10.1074\/jbc.R117.807560","article-title":"Peptide Splicing by the Proteasome","volume":"292","author":"Vigneron","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1182\/blood-2008-11-187633","article-title":"Exclusive Expression of Proteasome Subunit \u03925t in the Human Thymic Cortex","volume":"113","author":"Tomaru","year":"2009","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.4049\/jimmunol.173.6.3925","article-title":"Immunoproteasomes Down-Regulate Presentation of a Subdominant T Cell Epitope from Lymphocytic Choriomeningitis Virus","volume":"173","author":"Basler","year":"2004","journal-title":"J. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/eji.200636372","article-title":"No Essential Role for Tripeptidyl Peptidase II for the Processing of LCMV-Derived T Cell Epitopes","volume":"37","author":"Basler","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1073\/pnas.96.7.3859","article-title":"Ubiquitin-Dependent Degradation of I\u03baB\u03b1 Is Mediated by a Ubiquitin Ligase Skp1\/Cul 1\/F-Box Protein FWD1","volume":"96","author":"Hatakeyama","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Petroski, M.D. (2008). The Ubiquitin System, Disease, and Drug Discovery. BMC Biochem., 9.","DOI":"10.1186\/1471-2091-9-S1-S7"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0896-6273(03)00606-8","article-title":"The Ubiquitin Proteasome System in Neurodegenerative Diseases: Sometimes the Chicken, Sometimes the Egg","volume":"40","author":"Ciechanover","year":"2003","journal-title":"Neuron"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.bbmt.2013.05.011","article-title":"Effects of Bortezomib on the Immune System: A Focus on Immune Regulation","volume":"19","author":"Mohty","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1034\/j.1600-6143.2002.21006.x","article-title":"On the Role of Proteasomes in Cell Biology and Proteasome Inhibition as a Novel Frontier in the Development of Immunosuppressants","volume":"2","author":"Wu","year":"2002","journal-title":"Am. J. Transplant."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7164\/antibiotics.44.113","article-title":"Lactacystin, a Novel Microbial Metabolite, Induces Neurito-Genesis of Neuroblastoma Cells","volume":"44","author":"Fujimoto","year":"1991","journal-title":"J. Antibiot."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1126\/science.7732382","article-title":"Inhibition of Proteasome Activities and Subunit-Specific Amino-Terminal Threonine Modification by Lactacystin","volume":"268","author":"Fenteany","year":"1995","journal-title":"Science"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"7273","DOI":"10.1074\/jbc.271.13.7273","article-title":"Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin: A Central Role for Closto-Lactacystin \u03b2-Lactone","volume":"271","author":"Dick","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/cpb.47.1","article-title":"Total Synthesis and Biological Activity of Lactacystin, Omuralide and Analogs","volume":"47","author":"Corey","year":"1999","journal-title":"Chem. Pharm. Bull."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","article-title":"Proteasome Inhibitors: From Research Tools to Drug Candidates","volume":"8","author":"Kisselev","year":"2001","journal-title":"Chem. Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"27280","DOI":"10.1074\/jbc.271.44.27280","article-title":"Selective Inhibitors of the Proteasome-Dependent and Vacuolar Pathways of Protein Degradation in Saccharomyces Cerevisiae","volume":"271","author":"Lee","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade\u00ae: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1081\/CNV-120030218","article-title":"Development of the Proteasome Inhibitor VelcadeTM (Bortezomib)","volume":"22","author":"Adams","year":"2004","journal-title":"Cancer Investig."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2008.08.002","article-title":"Mechanisms of Proteasome Inhibitor Action and Resistance in Cancer","volume":"11","author":"McConkey","year":"2008","journal-title":"Drug Resist. Updates"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","article-title":"The Ubiquitinproteasome Pathway Is Required for Processing the NF-\u03baB1 Precursor Protein and the Activation of NF-\u03baB","volume":"78","author":"Palombella","year":"1994","journal-title":"Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.4049\/jimmunol.171.3.1515","article-title":"The Proteasome as a Lipopolysaccharide-Binding Protein in Macrophages: Differential Effects of Proteasome Inhibition on Lipopolysaccharide-Induced Signaling Events","volume":"171","author":"Qureshi","year":"2003","journal-title":"J. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","article-title":"Ixazomib: First Global Approval","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.04.008","article-title":"Competitive Landscape Report","volume":"96","author":"Teicher","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cbpa.2008.06.033","article-title":"Advances in and Applications of Proteasome Inhibitors","volume":"12","author":"Moore","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"620.4","DOI":"10.1096\/fasebj.2018.32.1_supplement.620.4","article-title":"Promoting Ubiquitination-mediated Degradation of Orai1 Protein by High Glucose in Glomerular Mesangial Cells","volume":"32","author":"Chaudhari","year":"2018","journal-title":"FASEB J."},{"key":"ref_125","first-page":"131","article-title":"New Insights into the Mechanisms and Importance of the Proteasome in Intracellular Protein Degradation","volume":"378","author":"Goldberg","year":"1997","journal-title":"Biol. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"8125","DOI":"10.4049\/jimmunol.174.12.8125","article-title":"Serum Amyloid A-Luciferase Transgenic Mice: Response to Sepsis, Acute Arthritis, and Contact Hypersensitivity and the Effects of Proteasome Inhibition","volume":"174","author":"Zhang","year":"2005","journal-title":"J. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1136\/ard.2008.097709","article-title":"Bortezomib Attenuates Murine Collagen-Induced Arthritis","volume":"68","author":"Lee","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_128","first-page":"92","article-title":"The Proteasome Inhibitor Bortezomib Inhibits the Release of NFkappaB-Inducible Cytokines and Induces Apoptosis of Activated T Cells from Rheumatoid Arthritis Patients","volume":"27","author":"Oerlemans","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1002\/art.27690","article-title":"The Proteasome Inhibitor Bortezomib Drastically Affects Inflammation and Bone Disease in Adjuvant-Induced Arthritis in Rats","volume":"62","author":"Yannaki","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/art.30177","article-title":"Proteasome Inhibition Aggravates Tumor Necrosis Factor-Mediated Bone Resorption in a Mouse Model of Inflammatory Arthritis","volume":"63","author":"Polzer","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e5760","DOI":"10.1097\/MD.0000000000005760","article-title":"Bortezomib Followed by Autologous Stem Cell Transplantation in a Patient with Rheumatoid Arthritis: A Case Report and Review of the Literature","volume":"95","author":"Liu","year":"2016","journal-title":"Medicine"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jbspin.2019.01.019","article-title":"Bortezomib Improved the Joint Manifestations of Rheumatoid Arthritis in Three Patients","volume":"86","author":"Lassoued","year":"2019","journal-title":"Jt. Bone Spine"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Wang, L., Liu, L., Hong, X., Liu, D., and Cheng, Z. (2021). Delanzomib, a Novel Proteasome Inhibitor, Combined with Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-\u03b1 Effect of Adalimumab. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.782385"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"13859","DOI":"10.1073\/pnas.95.23.13859","article-title":"NF-\u03baB Activation Provides the Potential Link between Inflammation and Hyperplasia in the Arthritic Joint","volume":"95","author":"Miagkov","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/art.27492","article-title":"Attenuation of Pain and Inflammation in Adjuvant-Induced Arthritis by the Proteasome Inhibitor MG132","volume":"62","author":"Ahmed","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/art.38095","article-title":"Role of ADAM-17, P38 MAPK, Cathepsins, and the Proteasome Pathway in the Synthesis and Shedding of Fractalkine\/CX3CL1 in Rheumatoid Arthritis","volume":"65","author":"Jones","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/1756-185X.12353","article-title":"Proteasome Inhibitor MG132 Modulates Inflammatory Pain by Central Mechanisms in Adjuvant Arthritis","volume":"20","author":"Ahmed","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm.1978","article-title":"A Selective Inhibitor of the Immunoproteasome Subunit LMP7 Blocks Cytokine Production and Attenuates Progression of Experimental Arthritis","volume":"15","author":"Muchamuel","year":"2009","journal-title":"Nat. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"110860","DOI":"10.1016\/j.intimp.2023.110860","article-title":"PR-957 Retards Rheumatoid Arthritis Progression and Inflammation by Inhibiting LMP7-Mediated CD4+ T Cell Imbalance","volume":"124","author":"Liu","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2174\/138945012803530053","article-title":"Proteasome Inhibitors: A New Perspective for Treating Autoimmune Diseases","volume":"13","author":"Fierabracci","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"10403","DOI":"10.1073\/pnas.96.18.10403","article-title":"Epoxomicin, a Potent and Selective Proteasome Inhibitor, Exhibits in Vivo Antiinflammatory Activity","volume":"96","author":"Meng","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Kisselev, A.F. (2022). Site-Specific Proteasome Inhibitors. Biomolecules, 12.","DOI":"10.3390\/biom12010054"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI16198","article-title":"Selective Inhibitors of the Osteoblast Proteasome Stimulate Bone Formation in Vivo and in Vitro","volume":"111","author":"Garrett","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/1078155212470388","article-title":"Carfilzomib: A New Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma","volume":"19","author":"Steele","year":"2013","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A Novel Orally Active Proteasome Inhibitor Induces Apoptosis in Multiple Myeloma Cells with Mechanisms Distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent Activity of Carfilzomib, a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway, against Preclinical Models of Multiple Myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","article-title":"Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma","volume":"10","author":"Bross","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1182\/blood.V114.22.4910.4910","article-title":"Dose Intensive Administration of PR-047, a Novel Orally Bioavailable Inhibitor of the 20S Proteasome, Is Well Tolerated in Experimental Animals","volume":"114","author":"Muchamuel","year":"2009","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Jones, B., Koch, A.E., and Ahmed, S. (2012). Pathological Role of Fractalkine\/CX3CL1 in Rheumatic Diseases: A Unique Chemokine with Multiple Functions. Front. Immunol., 2.","DOI":"10.3389\/fimmu.2011.00082"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/7\/2943\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:59:23Z","timestamp":1760029163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/7\/2943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":149,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["ijms26072943"],"URL":"https:\/\/doi.org\/10.3390\/ijms26072943","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]}}}